Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C65H89N9O25 |
Molecular Weight | 1396.4475 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)CCCC(O)=O)C7CCCCC7)[C@H](O)[C@H](C)O5)C(=O)CO)C(O)=C3C2=O
InChI
InChIKey=CZXGBIFEWYVYJY-NPLULESDSA-N
InChI=1S/C65H89N9O25/c1-28(2)19-37(60(91)69-36-21-47(98-30(4)53(36)84)99-42-23-65(96,43(79)27-77)22-34-49(42)57(88)51-50(55(34)86)54(85)33-13-9-14-41(97-5)48(33)56(51)87)70-61(92)38(25-75)72-59(90)35(17-18-44(66)80)68-64(95)52(31-11-7-6-8-12-31)73-62(93)39(26-76)71-58(89)29(3)67-63(94)40-20-32(78)24-74(40)45(81)15-10-16-46(82)83/h9,13-14,28-32,35-40,42,47,52-53,75-78,84,86,88,96H,6-8,10-12,15-27H2,1-5H3,(H2,66,80)(H,67,94)(H,68,95)(H,69,91)(H,70,92)(H,71,89)(H,72,90)(H,73,93)(H,82,83)/t29-,30-,32+,35-,36-,37-,38-,39-,40-,42-,47-,52-,53+,65-/m0/s1
Molecular Formula | C65H89N9O25 |
Molecular Weight | 1396.4475 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:45:04 GMT 2023
by
admin
on
Fri Dec 15 15:45:04 GMT 2023
|
Record UNII |
VDXVABRQTV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9855284
Created by
admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
|
PRIMARY | |||
|
207395-85-5
Created by
admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
|
PRIMARY | |||
|
C1853
Created by
admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
|
PRIMARY | |||
|
VDXVABRQTV
Created by
admin on Fri Dec 15 15:45:04 GMT 2023 , Edited by admin on Fri Dec 15 15:45:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
L-377,202 was approximately 15 times more effective than was conventional doxorubicin at inhibiting the growth of human prostate cancer tumors in nude mice when both drugs were used at their maximally tolerated doses.
|
||
|
ACTIVE MOIETY |
For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
|
||
|
ACTIVE MOIETY |
A prodrug in which a peptide is covalently conjugated with the anthracycline antineoplastic antibiotic doxorubicin.
|